Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study

Neurology

Volumn 46, Issue 6, 1996, Pages 1607-1612

  Confavreux, C ^a   Saddier, P ^b   Grimaud, J ^a   Moreau, Th ^a   Adeleine, P ^c   Aimard, G ^d  

^a Hopital de l'Antiquaille   (France)

^b IL   (United States)

^c HOSPICES CIVILS DE LYON   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN CANCER; SOLID TUMOR;

ADULT; AGE OF ONSET; AUTOIMMUNE DISEASES; AZATHIOPRINE; CARCINOGENS; CASE-CONTROL STUDIES; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEOPLASMS; RISK; SINGLE-BLIND METHOD;

EID: 0029934518     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.6.1607     Document Type: Article

References (34)

1. Reingold SC. Advances in the understanding and treatment of multiple sclerosis. Boston, Massachusetts, USA, 28-29 October 1992. J Neuroimmunol 1993;44:221-224.
2. Aimard G, Girard PF, Raveau J. Sclérose en plaques et processus d'auto-immunisation: traitement par les anti-mitotiques. Lyon Médical 1966;215:345-352.
3. Aimard G, Confavreux C, Ventre JJ, Guillot M, Devic M. Etude de 213 cas de sclérose en plaques traités par l'azathioprine de 1967 à 1982. Rev Neurol (Paris) 1983;139: 509-513.
4. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-1055.
5. Krikorian JG, Anderson JL, Bieber CP, Penn I, Stinson EB. Malignant neoplasms following cardiac transplantation. JAMA 1978;240:639-643.
6. Kinlen LJ, Peto J, Doll R, Sheil AGR. Cancer in patients treated with immunosuppressive drugs. Brit Med J 1981;282: 474.
7. Sheil AGR, Flavel S, Disney APS, Mathew TH. Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc 1985;17:1685-1688.
8. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990;323:1767-1769.
9. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649-1662.
10. Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 1979;300:452.
11. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78(suppl 1A):44-49.
12. Lhermitte F, Marteau R, Roullet E. Not so benign long-term immunosuppression in multiple sclerosis? Lancet 1984;i:276-277.
13. Confavreux C, Moreau T, Grimaud J, et al. Azathioprine and neoplasm in multiple sclerosis. J Neurol 1992;239(suppl 2): P458.
14. British and Dutch multiple sclerosis azathioprine trial group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;ii:179-183.
15. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989;39:1018-1026.
16. Goodkin DE, Daughtry MM, Vanderbrug-Medendorp SV. Incidence of malignancy following cyclophosphamide or azathioprine treatment of multiple sclerosis. Ann Neurol 1992;32:257.
17. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993;43:831-833.
18. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343:1249-1252.
19. Confavreux C, Moreau T, Wolfson C, et al. Natural history and prognosis in multiple sclerosis: the Lyon MS database. In: Battaglia MA, ed. Multiple Sclerosis Research. Amsterdam: Excerpta Medica, Elsevier Sciences Publishers, 1989:199-203.
20. Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European Database for Multiple Sclerosis. J Neurol Neurosurg Psychiatry 1992;55:671-676.
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
22. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300.
23. Kurtzke JF. Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology 1965;15:654-661.
24. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, CA: Lifetime Learning Publications, 1982.
25. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1: The analysis of case-control studies. Lyon: IARC, 1980.
26. Power®. Epicenter Software. Pasadena, CA, USA.
27. SAS/STAT - User's guide, Version 6. SAS Institute Inc., Cary, NC, USA.
28. Stazio A, Kurland LT, Bell LG, Saunders MG, Rogot E. Multiple sclerosis in Winnipeg, Manitoba: methodological considerations of epidemiologic survey. Ten year follow-up of a community wide study, and population re-survey. J Chron Dis 1964;17:415-438.
29. Sibley WA, Bamford CR, Laguna JF. Anamnestic studies in multiple sclerosis: a relationship between familial multiple sclerosis and neoplasia. Neurology 1978;28:125-128.
30. Wender M, Lenart-Jankowska D, Kowal P, Tokarz E. Comparative epidemiologic studies of multiple sclerosis and cancer of the large intestine in several provinces of Western Poland. Neurol Neurochir Pol 1987;21:207-311.
31. Lumsden CE. Multiple sclerosis and other demyelinating diseases. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology, vol 9. Amsterdam, The Netherlands: North Holland Publishing, 1970:232-233.
32. Allen IV, Millar JHD, Hutchinson MJ. General disease in 120 necropsy-proven cases of multiple sclerosis. Neuropath Appl Neurobiol 1978;4:279-284.
33. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193-1196.
34. Möller H, Kneller RW, Boice JD Jr, Olsen JH. Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol Scand 1991;84:214-220.